Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.

Clinical trial details

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Identifier

20190009

Sponsor

AMGEN INC

Principal Investigator

ENRIQUETA FELIP FONT

Service

Oncology

Study details

Tumor type: LUNG-NSCLC
Stage: Advanced
Main Investigational Agent : Targeted therapy
Phase: III
Randomization: Randomized

Molecular details

Biomarker: KRAS alt
Biomarker criteria: Mandatory
Prescreening: Central
Additional study population requirements: Mutated KRAS p.G12C

Drug details

Arm A: AMG510
Arm B: Docetaxel

Links

Clinical Trials GOV (NCT identifier): NCT04303780
EU Clinical Trials Register (eudraCT Identifier): 2019-003582-18